Get the Stockscreener App
43.58
2.66%
-1.19
After Hours:
43.85
0.27
+0.62%
Hims Hers Health Inc Stock (HIMS) Latest News
Super Bowl ad for weight loss drug sparks backlash - Good Morning America
Hims & Hers health chief commercial officer sells $314k in stock - Investing.com
Hims & Hers Health Executives Sell Shares Under Trading Plans - TradingView
‘Check before you inject’: Novo bites back at Hims & Hers Super Bowl ad - MM+M Online
Hims Stock: The Future of Telehealth Investment? - Reporteros del Sur
Hims Hers Health stock adds to gains amid Super Bowl ad impact - MSN
Hims & Hers Health Stock Gains 77% YTD as Earnings Approaching - AskTraders
Hims & Hers' Super Bowl ad sparks backlash - Good Morning America
Why Hims & Hers Health (HIMS), Tempus AI (TEM) and Teladoc (TDOC) Are Up Big Today - MSN
State of Alaska Department of Revenue Invests $2.63 Million in Hims & Hers Health, Inc. (NYSE:HIMS) - MarketBeat
Hims & Hers stock price target according to the C&H pattern - MSN
Hims & Hers Takes Aim At Big Pharma In Controversial Super Bowl Ad — Retail Loves The Fight - MSN
Hims & Hers Health: Explosive Growth Potential Ahead - Seeking Alpha
Hims & Hers Health (NYSE:HIMS) Sets New 52-Week HighStill a Buy? - MarketBeat
Hims & Hers Super Bowl controversy: What the ad left out about its 'alternative' weight-loss drugs - Livescience.com
Monday Morning (Advertising) Quarterback – Unprecedented Hims & Hers Super Bowl Ad Has Legislators Concerned - The National Law Review
Why Hims & Hers Health Stock Crushed Novo Nordisk and Viking Therapeutics Today - The Motley Fool
On Super Bowl Sunday, ads for junk food and dessert bump up against weight-loss drugs - Marketing Brew
Hims & Hers Health Unusual Options Activity For February 10 - Benzinga
Now BIO bashes Hims & Hers as obesity ad aires - The Pharma Letter
GLP-1 ad battle—Ozempic and Wegovy maker responds to Hims & Hers Super Bowl debut - Ad Age
Hims & Hers Super Bowl ad stirs up controversy with lawmakers - Yahoo Finance
Hims & Hers Health: Meme Potential Could Propel Explosive Growth - Seeking Alpha
Hims Super Bowl Ad Spotlights Weight-Loss Drug Copycats as Clock Ticks on Their Business - Yahoo Finance
Hims & Hers Stock Bounces After Super Bowl Ad - The Wall Street Journal
Hims & Hers aired a Super Bowl ad for weight loss drugs. It alarmed health experts and senators. - Yahoo Life
What is compounded semaglutide and is it safe? The weight loss drugs Hims & Hers is selling, explained. - Yahoo Life
Hims & Hers Super Bowl Commercial 2025: All About Weight Loss, Obesity, & How to Get Medications from Your Phone - Just Jared
SF company airs controversial Super Bowl ad despite multiple objections - SFGATE
Kercheville Advisors LLC Takes Position in Hims & Hers Health, Inc. (NYSE:HIMS) - MarketBeat
Hims & Hers Super Bowl Spot Draws Drug-Industry Backlash - The Wall Street Journal
Hims & Hers Health (NYSE:HIMS) Stock Price Up 4.5%Here's What Happened - MarketBeat
Will Hims & Hers Become the Next Big Stock Win? Dive Into the Trends! - Reporteros del Sur
Oluyemi Okupe Sells 11,581 Shares of Hims & Hers Health, Inc. (NYSE:HIMS) Stock - MarketBeat
Hims & Hers Health, Inc. (NYSE:HIMS) CEO Andrew Dudum Sells 100,000 Shares - MarketBeat
Hims & Hers Health, Inc. (NYSE:HIMS) Insider Sells $146,600.90 in Stock - MarketBeat
Two U.S. senators slammed an S.F. telehealth company’s Super Bowl ad. Here’s why - San Francisco Chronicle
Hims & Hers Super Bowl commercial draws lawmaker scrutiny - Seeking Alpha
Pacer Advisors Inc. Invests $374,000 in Hims & Hers Health, Inc. (NYSE:HIMS) - MarketBeat
Lawmakers, health experts call on FDA to pull Hims & Hers Super Bowl ad - Healthcare Brew
Hims & Hers Health (NYSE:HIMS) Stock Quotes, Forecast and News Summary - Benzinga
Hims and Hers Superbowl Ad Draws Controversy Over Safety - Managed Healthcare Executive
Super Bowl ad for Hims & Hers' weight loss drug sparks backlash - AOL
Hims’ Super Bowl spot for compounded GLP-1 drugs draws Senate scrutinyMM+M - MM+M Online
IBD 50 Stock Hims & Hers Faces Backlash Over Provocative Super Bowl Ad - Yahoo
Hims & Hers faces backlash over 'misleading' Super Bowl ad—but it didn't stop stock from jumping over 11% - Fast Company
A Super Bowl Ad Sparks Controversy and Signals a New Era in U.S. Health - Barron's
Hims Promises Affordable Weight Loss—But Is It Just a $79 Monthly Pipe Dream? - breakingac.com
Hims & Hers Super Bowl ad draws ire from lawmakers - Modern Healthcare
Hims & Hers Jumps 8.35% After Controversial Super Bowl Ad - GuruFocus.com
Hims & Hers stands firms in face of PhRMA slur - The Pharma Letter
Hims & Hers jumps ahead of controversial Super Bowl commercial - MSN
Hims & Hers stock up ahead of Super Bowl ad (HIMS:NYSE) - Seeking Alpha
Super Bowl Ad Selling Weight Drug Shows Wild West of Copycats (1) - Bloomberg Law
Weight Loss Drug Super Bowl Ad Raises Questions About Compounded Vs. Branded Meds - Forbes
Hims & Hers Health Unusual Options Activity - Benzinga
Hims & Hers Stock (HIMS) Falters on Backlash Over Super Bowl Ad - TipRanks
Hims No-Insurance, No-Injection Weight Loss Plan—Brilliant Innovation or Dangerous Shortcut? - Peninsula Daily News
Brokerages Set Hims & Hers Health, Inc. (NYSE:HIMS) Target Price at $25.13 - MarketBeat
Hims Telehealth Company Under Fire For Super Bowl Ad - Science 2.0
9.31%
0.83%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):